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Abstract: Ipilimumab is approved for adjuvant melanoma treatment at a dose of 10 mg/kg, but its use
is limited owing to high toxicity and treatment-associated costs. We retrospectively analyzed 29 patients
who underwent complete resection of stage IIC–III melanoma and were treated with ipilimumab 3 mg/kg
in an adjuvant setting. The aim was to assess development of adverse events (primary endpoint) and to
evaluate survival outcomes (secondary endpoint) under adjuvant treatment with ipilimumab in a real-life
setting. Immune-related adverse events (irAE) of all grades were reported in 72.4% of patients, grade
3 in 5.3% (n=2), and none for grade 4 or 5. Immune-related hypophysitis resolved in 3/8 (37.5%) and
immune-related thyroiditis in 7/10 (70%) cases, whereas the others remained on substitution drugs. The
rest irAEs affected the gut (n=8), skin (n=5), liver (n=2), and uvea (n=2) and resolved completely. Only
one patient required tumor necrosis factor-฀ owing to grade 3 colitis. Hospitalization was required in five
cases owing to irAE (four colitis and one hypophysitis). At a median follow-up of 9.7 (1.7–16.8) months,
65.5% of the patients were free of disease. Median progression-free survival was 15.1 months, and median
overall survival was not reached yet. Ipilimumab 3 mg/kg for the adjuvant treatment of high-risk patients
with fully resected melanoma favors a better safety profile compared with the approved dose of 10 mg/kg
in the same setting. Although its limited application owing lately promising data of antiprogrammed cell
death protein-1 treatment, it may be considered as additional option or second-line treatment after fully
resected disease recurrence under antiprogrammed cell death protein-1 treatment.
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Ipilimumab is approved for adjuvant melanoma treatment at
a dose of 10mg/kg, but its use is limited owing to high
toxicity and treatment-associated costs. We retrospectively
analyzed 29 patients who underwent complete resection of
stage IIC–III melanoma and were treated with ipilimumab
3mg/kg in an adjuvant setting. The aim was to assess
development of adverse events (primary endpoint) and to
evaluate survival outcomes (secondary endpoint) under
adjuvant treatment with ipilimumab in a real-life setting.
Immune-related adverse events (irAE) of all grades wereAQ5
reported in 72.4% of patients, grade 3 in 5.3% (n=2), and
none for grade 4 or 5. Immune-related hypophysitis resolved
in 3/8 (37.5%) and immune-related thyroiditis in 7/10 (70%)
cases, whereas the others remained on substitution drugs.
The rest irAEs affected the gut (n= 8), skin (n= 5), liver
(n= 2), and uvea (n= 2) and resolved completely. Only one
patient required tumor necrosis factor-α owing to grade 3
colitis. Hospitalization was required in five cases owing
to irAE (four colitis and one hypophysitis). At a median
follow-up of 9.7 (1.7–16.8) months, 65.5% of the patients
were free of disease. Median progression-free survival was
15.1 months, and median overall survival was not reached yet.
Ipilimumab 3mg/kg for the adjuvant treatment of high-risk
patients with fully resected melanoma favors a better safety
profile compared with the approved dose of 10mg/kg in
the same setting. Although its limited application owing
lately promising data of antiprogrammed cell death protein-1
treatment, it may be considered as additional option or
second-line treatment after fully resected disease recurrence
under antiprogrammed cell death protein-1 treatment.
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Introduction
Melanoma shows rising incidence rates worldwide, exhibiting
the highest rates in Australia, New Zealand, and Switzerland
[1]. Although the incidence rates of most common cancer
types have decreased during the past decades, melanoma
incidence rates have increased continuously, affecting virtually
all age classes [2]. Fair skin type and extensive intermittent
UV radiation are well-known risk factors [3]; however,
melanoma can affect virtually any individual with the com-
bination of specific oncogene mutations [4].
Despite the excellent survival of early stages [5], advanced
stages imply a poor prognosis if left untreated. Patients with
stage III melanoma show high heterogeneity with 10-year
survival rates of 88–24% depending on the subcategory of the
stage III types: stage IIIA reveals a 10-years overall survival
(OS) rate of 88%, IIIB of 77%, IIIC 60%, and IIID of 24%.
Although the prognosis of stage IIA and B presents a 10-years
OS of 82–88%, that of stage IIC declines to 75% [5].
To save patients from progression into stage IV disease, dif-
ferent adjuvant treatment settings have been implemented for
patients at risk for progression: interferon-α achieved an 8%
improvement of 10-year OS in patients with melanoma with
micrometastases in the sentinel lymph node biopsy and
ulcerated primary tumors [6]. Comparison of high-dose versus
low-dose or intermediate-dose interferon could not prove
superior efficacy but was accompanied with stronger andmore
severe adverse events (AEs) [7]. Other treatment strategies
such as high-dose interleukin-2 was not convincing in
improvement of OS [8].
Ipilimumab is a fully human IgG1 monoclonal antibody
that blocks the cytotoxic T lymphocyte-associated antigen
4. It achieved Food and Drug Administration (FDA)
approval for stage IV disease in 2011 at a dosage of 3mg/
kg. AEs comprise mainly autoimmune toxicity against
organs such as pituitary gland, gut and liver system, lung,
and thyroid glands among others, and are treatment rela-
ted, that is, 37 versus 18% for 10 versus 3mg/kg dosage in
advanced stages. Most of these AEs are related to diarrhea
or colitis (10 vs. 6%), hepatitis (3 vs. 1%), or hypophysitis
(3 vs. 2%) [9]. Application in an adjuvant setting for
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patients with stage III melanoma at a dosage of 10mg/kg
resulted in higher rates of recurrence-free survival (RFS)
(40.8 vs. 30.3%) and OS (65.4 vs. 54.4%) compared with
placebo in the adjuvant setting [10]. Approval from the US
FDA was gained for this population at this dose as pro-
vided in the approval study in 2015 [10]. However, mainly
owing to high toxicity and high treatment-associated costs,
ipilimumab was not reimbursed in Europe or Australia for
the adjuvant treatment of melanoma in the aforemen-
tioned schedule.
In this context, we applied adjuvant ipilimumab in the
conventional treatment dose of 3 mg/kg every 3 weeks in
patients with high-risk melanoma after complete lymph
node resection or excision of in-transit disease during
October 2016 and May 2017. In the following sections,
we present our real-life experience data using this treat-
ment modality.
Patients and methods
Patient’s selection and data acquisition
We conducted a single-center retrospective study with
patients with stage IIC–III melanoma who were treated
with adjuvant ipilimumab at the Dermatology Department
of the University Hospital Zurich between October 2016 and
May 2017. Stage III disease was subclassified as IIIA, IIIB, or
IIIC according to the American Joint Committee on Cancer
7th ed. Patients had to have at least one cycle of ipilimumab
for being qualified for the analysis. Ipilimumab was admi-
nistered intravenously at a dose of 3mg/kg every 3 weeks for
a maximum of four cycles based on the reimbursed protocol
for stage IV disease. Eligible patients required complete
lymphadenectomy or complete resection of in-transit disease
within 12 weeks before the first infusion of ipilimumab.
Evaluation of disease was radiologically performed with
PET/computed tomography scans every 12 weeks.
Treatment was not applied in pregnant or breastfeeding
women and in patients with an active severe autoimmune
disease, excluding Hashimoto thyroiditis. Treatment had
to be stopped and adapted in case of disease progression.
Demographical and clinicopathological parameters and data
on disease course of eligible patients were collected by
reviewing patients’ electronic medical files. AE were docu-
mented with the use of the Common Terminology Criteria
for Adverse Events version 4.03. Resolution of an immune-
related adverse event (irAE) was defined as an improvement
to grade 1 or less. OS was defined as the length of time in
months from treatment start to either death or last follow-up
(analysis accounted for censored survival times). Progression-
free survival (PFS) was defined as the length of time in
months from treatment start until to progression or recur-
rence or melanoma-related death. Local ethics committee
approved, as well as written informed consent for tissue
storage, including retrospective analysis, with collection of
clinical/laboratory/histological information before collection
was obtained (KEK-ZH-Nr. 647, 800).
Primary end point of the study analyzed quality and quantity
as well as onset of AEs under adjuvant ipilimumab in a real-
life setting. Secondary end point addressed survival out-
comes (median OS and PFS) following treatment initiation.
Moreover, we performed a systematic literature research and
compared our study cohort with available prospective or
retrospective trials to evaluate whether the incidence of AES
of our cohort is similar to that reported in the literature.
Statistical analysis
Statistical analysis of the data was performed using GraphPad
Prism software version 7.0 (GraphPad Software, San Diego,
California, USA). Kaplan–Meier survival curves were per-
formed using log-rank test. Statistical analysis was done using
descriptive analysis. P values of less than 0.05 were considered
statistically significant.
Results
We retrospectively treated 29 (14 females and 15 males)
patients with a median age of 52.4 (range: 15.4–76.1)
years. One (3.45%) patient had stage IIC melanoma,
seven patients had stage IIIA (24.14%), 10 (34.48%)
patients had stage IIIB, and 11 (37.93%) patients had stage
IIIC melanoma. Twenty-one (72.41%) patients completed
the set of four infusions of ipilimumab, six patients received
three infusions (20.70%), one patient two infusions (3.45%),
and another patient one cycle (3.45%).
The mean number of treatment AQ6cycles were 3.59 (3.29–3.88,
SD: 0.78). Mean days of treatment duration was 54.48
(48.12–60.85, SD: 16.74). Discontinuation rate was 27.58% (8
of 29 patients). Treatment was stopped in patient 15 owing
to the patient’s request. Patient 22 received only two and
patient 25 only three doses of ipilimumab owing to disease
progression (mentioned later). In the other patients, treat-
ment was stopped owing to AE (mentioned later). For fur-
ther details, please refer to Table 1 (Patients’ characteristics).
Immune-related adverse events
In those 29 patients, 38 irAEs were reported during
treatment with adjuvant ipilimumab (mean 1.31/patient).
In total, 21 (72.4%) patients experienced at least one irAE,
and only eight patients did not experience any irAE (27.59%):
16 (42.11%) irAEs were grade 1 and 20 (52.63%) were grade
2, whereas only two (5.26%) were grade 3 irAEs (Table 2).
Autoimmune toxicities affected mostly thyroid (n=10,
26.32%) or pituitary glands (each n=8, 21.05%), gut system
(n=8, 21.05%), and the skin (n=6, 15.79%). Skin AEs con-
sisted of two (5.26%) events of pruritus, one (2.63%) mild
erythema, and three (7.90%) cases of mild maculopapulous
exanthema. Owing to the mild courses and rapid treatment
response, no biopsies were taken. Increased pancreatic
enzymes without further implication, uveitis, and hepatitis
were detected in two (5.26%) cases each. However, the
hepatitis in patient 16 cannot be clearly attributed to
the ipilimumab treatment by itself, as the patient was
elsewhere also treated with Traditional Chinese Medicine.
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Table 1 Patients’ characteristicsAQ7





















metastasesa First follow-up Last follow-up
Follow-up until
next treatment
start (months) Following treatment
1 Female 68 NM Yes >4 Unknown 3 IIIC 2 Macro 2 Free of disease Free of disease 14.8 None
2 Male 58 NM No >1≤2 Unknown 3 IIIB 1 None 1 Free of disease Free of disease 15.9 None
3 Male 50 SSM No >2≤3 Unknown 4 IIIA 2 Macro 1 Free of disease Disease recurrence 9.7 Nivolumab; TVEC
4 Male 76 LMM No ≤1 1, 5 4 IIIB 1, 2 No SLNB 1 Free of disease Disease recurrence 10.1 Nivolumab
5 Male 59 CUP NA NA 1 4 IIIC 2 No SLNB 2 Free of disease Free of disease 12.9 None
6 Male 35 NM Yes >2≤3 1 4 IIIC 1, 2 Extranodal 1 Disease recurrence Disease recurrence 16.8 Combi-i Studie
CPDR001F2301;
NCT02967692
7 Female 45 NM Yes >2≤3 1 4 IIIC 1, 2 Micro 2 Free of disease Free of disease 13.7 None
8 Female 35 NM NA >1≤2 Unknown 4 IIIB 2 Macro 1 Free of disease Free of disease 14.0 None
9 Male 60 CUP NA 2 3 IIIB 1, 2 No SLNB 1 Free of disease Free of disease 14.4 None
10 Male 52 SSM No >1≤2 Unknown 3 IIIA 2 Micro 1 Free of disease Free of disease 15.0 None
11 Female 71 CUP NA NA 3 4 IIIC 2 NA 2 Free of disease Disease recurrence 14.8 Surgery
12 Male 47 SSM No >1≤2 1 2 IIIB 1, 2, 3 None 2 Disease recurrence Disease recurrence 3.3 Nivolumab/T-
VEC ±Pembro
(Masterkey 265)
13 Male 40 SSM No >2≤3 2 4 IIIB 1, 3 None 2 Free of disease Free of disease 12.8 None
14 Female 69 SSM No >1≤2 1 4 IIIB 1 No SLNB 1 Free of disease Free of disease 10.1 None
15 Female 45 Ex neavo Yes >1≤2 Unknown 1 IIIB 2 Macro 1 Free of disease Free of disease 3.9 None
16 Female 53 SSM No >2≤3 Unknown 4 IIIA 2 Macro 1 Free of disease Free of disease 13.6 None
17 Male 54 NM No >2≤3 Unknown 4 IIIA 2 Macro 1 Free of disease Free of disease 9.9 None
18 Female 51 SSM No >4 Unknown 4 IIIA 1, 2 No SLNB 2 Disease recurrence Disease recurrence 5.7 Surgery
(lymphadenectomia,
nivolumab
19 Female 67 CUP NA NA 3 4 IIIB 1, 3 No SLNB 1 Disease recurrence Free of disease 3.6 Pembrolizumab
20 Male 66 SSM0 Yes > 4 Unknown 4 IIC 2 None 0 Free of disease Free of disease 9.3 None
21 Male 51 ALM No >1≤2 2 4 IIIC 1, 2 None 2 Disease recurrence Disease recurrence 5.3 (death) Nivolumab; VP;
CLXH254X2101
22 Female 72 NM Yes >1≤2 1 2 IIIC 1 No SLNB 2 Disease recurrence Disease recurrence 1.7 Nivolumab/T-
VEC ±Pembro
(Masterkey 265)
23 Female 73 Unclassifiable NA NA 2 4 IIIC 1 Lymph
node: 0/1
(no SLNB)
0 Disease recurrence Disease recurrence 5.9 Pembrolizumab
24 Female 32 SSM No >1≤2 Unknown 4 IIIA 2 Macro 1 Free of disease Free of disease 6.6 None
25 Female 67 NM NA >1≤2 1 3 IIIB 3 Micro 2 Disease recurrence Disease recurrence 1.8 BRAF/MEK-I
(Tafinlar/Mekinist)
26 Male 35 SSM No >1≤2 1 4 IIIC 2 Macro 2 Free of disease Disease recurrence 9.6 Pembrolizumab
27 Male 49 NM Yes >4 1 4 IIIC 2, 3 None 2 Free of disease Free of disease 5.8 None
28 Male 40 Unclassifiable Yes >2≤3 1 4 IIIC 3 Micro 2 Free of disease Free of disease 7.7 None
29 Female 15 Unclassifiable No >1≤2 1 4 IIIA 2 Macro 1 Free of disease Free of disease 9.4 None
aAt onset of treatment.
CR, complete response; NA, not available; PD, progressive disease type of metastases (owing to PET-computed tomography); PR, partial response: SLNB, sentinel lymph node biopsy; 1, in-transit/cutaneous; 2, locoregionale



























































































The same applies to patient 19, who was treated with
TVECAQ8 ± and pembrolizumab before the ipilimumab
treatment in the setting of theMasterkey-265 trial. Therefore,
hypophysitis and thyroiditis in this patient might have
occurred in the context of accumulation of both checkpoint
inhibitor agents. One patient experienced a mild reactivation
of his known psoriasis arthritis even before the treatment start
(grade 1) as his hitherto treatment with infliximab had to be
stopped before treatment with ipilimumab. Therefore, we
did not include him into the statistics of irAE. We observed
no pneumonitis, nephritis, nor cardiac involvement in our
patient population. There were further no noteworthy other
or new AEs recorded than the aforementioned irAEs.
Skin was the first affected organ (mean: 6.3 weeks), fol-
lowed by pancreas (mean: 6.8 weeks), thyroid gland
(mean: 7.5 weeks), gut system (mean: 8.5 weeks), and
pituitary gland (mean: 10.9 weeks). Hepatitis occurred
with a mean delay of 13.9 weeks, and uveitis with a delay
of 17.7 weeks (Figs 1 and 2 and Table 2). The highest
grade of irAE was related to colitis (grade 3), whereas
other irAEs manifested with grade 2 at most – besides the
pancreas, which achieved only grade 1 irAE. Duration of
the irAE is presented in Table 2. It was foremost highest
in hypophysitis (mean: 219.5 days), of which most did not
recover (62.5%), followed by thyroiditis (mean: 85 days),
with only three patients requiring levothyroxine. Mean
duration of AEs in uveitis was 45 days, followed by colitis
(mean: 9.1 days) and skin rash (mean: 8 days).
Treatment of immune-related adverse events
Systemic steroids were required in 41% of the treated
patients (n= 12), accounting for 30% of all irAEs (15 cases
of 50 recorded irAEs). Taken together, 24% of the trea-
ted patients required systemic steroids owing to hypo-
physitis (n= 7), 21% owing to colitis (n= 6), and 3%
owing to uveitis (n= 1). Cutaneous AEs were treated
with topical therapy consisting of class III steroids and




grade Onset (mean) (days)
AE resolution
(%)






Thyroiditis 10 2 55.2 (38–83) 70 85 (9–386) 0 0 0
Hypophysitis 8 2 76.0 (4–175) 37.5 219.5 (10–398) 7 0 1
Colitis 8 3 59.3 (5–106) 100 9.1 (2–21) 6 1 4
Skin rash 6 2 33.2 (8–62) 100 8.0 (5–14) 0 0 0
Hepatitis 2 2 97.0 (96–98) 100 84.5 (28–141) 0 0 0
Uveitis 2 2 124.0 (109–139) 100 45.0 (30–60) 1 0 0
AE, adverse events.
Fig. 1
Immune-related adverse events differentiated by grades 0–3 following Common Terminology Criteria for Adverse Events (CTCAE) 4.03.
Fig. 2
Onset of immune-related adverse events.
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polidocanol, 5%. No systemic steroids were required in
all of these cases.
Hospitalization was required in five patients owing to
irAE (17.24% of all patients): in four patients owing to
colitis and in the other owing to hypophysitis. Tumor
necrosis factor-α in combination with systemic steroids
was necessary in one patient with pancolitis; in six
patients with colitis, systemic steroids were sufficient;
and the one patient with colitis did not require any sys-
temic anti-inflammatory treatment at all.
Levothyroxine substitution was needed in two patients
for bridging until reconstitution of the thyroid glands.
Hydrocortisone substitution was necessary in seven of
eight (87.5%) patients with hypophysitis; only one
patient did not require specific treatment for reconstitu-
tion of the pituitary gland (12.5%). In six (75%) of these
patients with hypophysitis, hydrocortisone treatment is
still ongoing until today.
Resolution of adverse events
Ipilimumab was discontinued in six patients owing to
AEs (6/29) (20.6%); in one patient after one, in another
patient after two, and in four patients after three cycles of
ipilimumab.
All irAEs affecting the gut system, skin, liver, uvea, and
pancreas resolved completely after treatment of irAE
and/or pausing ipilimumab treatment. Thyroiditis was
not recovered in three of 10 (30%) cases and hypophysitis
in five of eight (62.5%) cases.
Taken together, six irAEs resulted in a durable damage
(15.80% of all irAE), where five of these related to the
pituitary gland (13.56% of all irAE), and one to the
thyroid gland (2.63% of all irAE) of a patient who
experienced also durable damage of the pituitary gland.
Interestingly, this patient was afterward treated with
nivolumab (patient 18).
Efficacy
At the first follow-up 3 months after treatment start, we
recorded 19 (65.52%) patients free of disease and nine
(31.03%) patients with a disease recurrence. At a median
follow-up of 9.7 (1.7–16.8) months, 11 (37.93%) patients
experienced disease recurrence, whereas 18 (62.07%)
patients were free of disease. A 15-year-old child did not
receive PET-computed tomography scans owing to the
radiation exposure, but PET-MRI was done instead.
Median PFS was 15.1 months, and median OS was not
reached (Figs 3 and 4). One patient died 5.9 months after
onset of treatment owing to disease progression, and 11
(37.93%) patients required subsequent treatment after
disease progression (Table 1).
There was no correlation between disease recurrence and
S100 (P= 0.498) but a trend to higher lactate dehy-
drogenase levels at onset of treatment (P= 0.083).
Patients who had to quit treatment preterm owing to
irAE did not have a higher incidence of disease relapse
(P= 0.385). Altogether, there was no correlation of grade
of irAE and disease recurrence (P=0.183).
Discussion
To the best of our knowledge, this analysis represents
the first report to assess the safety profile and efficacy of
adjuvant ipilimumab in real-setting data in the afore-
mentioned dosage.
In this retrospective single-center study involving
patients with fully resected high-risk melanoma, 72.4%
(21/29) of the patients under adjuvant ipilimumab at an
intermediate-dose of 3 mg/kg (ipi3) administered every
3 weeks for the maximum of four cycles experienced at
least one irAE.
We applied a different dosage schedule of ipilimumab
than the one that has been FDA approved in the adju-
vant setting, which definitely aggravates direct compar-
ison with the current literature data. However, given the
Fig. 3
Progression-free survival (before adjacent treatment).
Fig. 4
Overall survival (before following treatment).
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high toxic effects and cost of treatment with 10 mg/kg,
justified questions have been raised whether ipilimumab
should be given at a dose of 10 mg/kg or lower. Based on
an unplanned analysis of the ECOG 1609 trial, which
evaluates 1 year of treatment with ipi3, ipilimumab at
10 mg/kg (ipi10), or high-dose interferon, no substantial
differences in PFS for patients treated with 3 mg/kg
compared with 10 mg/kg were noted [11]. In our study
cohort, patients with micrometastatic disease in sentinel
lymph node biopsy underwent complete lymphade-
nectomy before scheduled adjuvant treatment. Complete
lymphadenectomy was also mandatory in all adjuvant
trials to date. Taking into account the results of the
Multicenter Selective Lymphadenectomy Trial-II and
the Dermatologic Cooperative Oncology Group trial [12,
13], complete lymphadenectomy is not associated with an
OS benefit. Although adjuvant therapy seems reasonable
in the subgroup of patients who are not undergoing a
completion lymph node dissection, data from clinical
trials are currently missing for this recommendation.
Ipilimumab is known to exert irAEs in both the intermediate-
dose of 3mg/kg and in the high-dose of 10mg/kg in the
advanced disease stages [14,15]. Severe irAEs have been
reported to be dose dependent and occur frequently under
combination immunotherapy with ipilimumab and nivolumab
[9,16].
According to ECOG 1609 again, 36% of the analyzed
patients with ipi3 experienced grade 3 irAEs [11], whereas
only 7% (2/29) grade 3 AEs were noticed in our study.
Moreover, none of our patients experienced a grade 4 AE.
However, interpretation of this difference has to be made
carefully owing to the small number of our study cohort. In
the recent published study of ipi10 versus nivolumab 3mg/kg
in the adjuvant setting, 98.5% of patients experienced at least
one AE in the ipilimumab group; grade 3 or 4 AEs were
reported in 45.9% [17]. Similar irAE rates were reported in the
Checkmate 029 trial of ipi10 versus placebo (all grade irAE
90.4, grade 3–4 41.6%) [10]. On the contrary, only 72.4% of
our study cohort experienced at least one irAE with the mean
cycle duration being 3.59, highlighting the better tolerability
of the aforementioned dosage schedule underlying the dose-
related toxicity. Most common irAEs experienced with ipi10
were the following: 63% skin toxicities, 46% gastrointestinal-
toxicities, 24.4% hepatitis, 37.8% endocrine, and 16.3% of
hypophysitis [17]. Conversely, we report on lower AE rates
with ipi3: 15.79% skin, 21.05 gastrointestinal, 5.26% hepatitis,
and 26.32% endocrine toxicities. Although direct comparison
cannot be made (retrospective vs. prospective multicenter
design and different dosages), the differences in AEs are
unquestionable (Table 3).
The rate of AEs in our study that led to the treatment
discontinuation was 20.6% (6/29), being definitely less
than the 42.6% reported with ipi10, though higher than
the 5% reported in the Checkmate 209–238 trial with
adjuvant nivolumab (Table 3) [10,17]. Compared with
stage IV disease with ipi3, where only 63% of patients
experienced at least one irAE, we report on higher AE
rate of any rate in the adjuvant setting [9]. This could be
explained by the different immunity in stage III patients
leading to higher AE rates in adjuvant setting. It is known
that both anti-cytotoxic T lymphocyte-associated antigen
4 and antiprogrammed cell death protein-1 (PD-1) anti-
bodies induce CD8+ effector memory T-cells, which then
play an important role not only for immune surveillance but
potentially also for the development of irAEs [18].
Two patients experienced grade 2 uveitis under adjuvant
ipilimumab. The symptoms have slowly improved under
steroid treatment and were completely resolved. Ocular
irAE are very rare and have been reported in less than 1%
of patients receiving ipilimumab. As stated in a systemic
review of 11 clinical trials and 4965 patients, the inci-
dence of uveitis ranged from 0.3 to 6% [19]. No incidence
of uveitis was recorded in the EORTC 18071 trial with
ipi10 [20].
The rest of the observed irAEs involved skin, gastrointestinal
tract, and endocrine organs and were easily managed, with
only one patient requiring, substantial to steroid treatment,
therapy owing to colitis. Moreover, most irAEs resolved in
accordance with the established management guidelines with
the exception of the patients who experienced endocrino-
pathy and hypophysitis, who continue to take replacement
therapy.
Interestingly, 62.1% of our study population (18/29) were
free of disease at last follow-up (median follow-up time:
9.7 months), whereas only one patient died owing to
rapid disease progression within 5.9 months after treat-
ment onset. Similar RFS rates (60.8%) were reported
within the Checkmate-238 study with ipi10 at 12-month
follow-up [17]. The ECOG 1609 trial demonstrated no
difference in RFS in ipi3 and ipi10 (54% with ipi10 and
56% with ipi3) at 3.1-year follow-up [11]. In the same
study and at 12-month follow-up, RFS rates with ipi3
were 70%; this 8% numerical difference compared with
our RFS rates could be explained by the low number of
patients included in our study. It is clear that owing to
Table 3 Comparison of adverse events in adjuvant ipilimumab treatment with literature
Dosage/clinical trial protocol Ipi3 4c/3we (real-life) Ipi10 (Checkmate 238) Ipi10 (Checkmate 029) Ipi3 (E1609)
All grade AEs (%) 72.4 98.5 90.4 98.6
Grade 3–4 (%) 7 45.9 41.6 36
Treatment discontinuation due to AEs 20.6 42.6 NA 35.2
AEs, adverse events; ipi3, ipilimumab 3mg/kg; c, cycles; 3/we, every 3 weeks; ipi10, ipilimumab 10mg/kg; NA, not available.
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limitations such as the retrospective study design, short
follow-up time, and small number of patients, none of the
conclusions regarding the efficacy of the administered
ipilimumab protocol can be made.
Recently, nivolumab, a monoclonal IgG4 anti-PD-1, showed
significant superior relapse-free survival (RFS) in a phase 3
clinical trial compared with ipilimumab (66.4 vs. 52.7%), with a
hazard ratio (HR) of 0.65 (P<0.0001), at 18-month follow-up
[17]. Based on this finding, nivolumab gained FDA approval
as an adjuvant treatment for patients with melanoma with
high-risk for relapse. Similarly, and in the same setting,
Keynote-054 met its primary end point with a RFS HR for
pembrolizumab of 0.57 [21]. Along with these agents, inhibi-
tion of the MAPK pathway is an additional option in patients
harboring a BRAF V600 mutation, owing to an exceptional
activity with OS benefit and a 53% reduction for relapse with
the combination of dabrafenib and trametinib (HR: 0.47; 95%
confidence interval: 0.39–0.58; P<0.0001) [22].
Conclusion
Taking into account the impressive new data in the
adjuvant field, the substantial toxicity related to ipili-
mumab and the superior efficacy of nivolumab and
pembrolizumab, the future of the former as monotherapy
in any dosage schedule seems limited. As these results
entirely affect the landscape of the adjuvant treatment,
there seems to be limited application of ipilimumab in
the aforementioned patient cohort. However, it can be
concluded that ipi3 favors a better safety profile com-
pared with the toxicity spectrum already defined for this
drug at the currently approved dose of 10 mg/kg in the
same setting, and therefore, it may be still considered as
an additional option or second-line treatment option for
fully resected melanoma in high-risk individuals after
disease-recurrence during anti-PD-1 or kinase inhibitor
treatment. Besides, its contribution as a synergic agent to
anti-PD-1 in the adjuvant setting is being currently
investigated in an ongoing clinical trial (NCT01844505).
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